Study S001790

A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04261933
Acronym: SURE GERMANY
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 789
Start: 2020-02-13
Primary completion: 2021-05-25
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1241-6291

Registered primary outcomes

Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)]
Change in HbA1c [Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006869	Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes. Vilsbøll T, Diabetes, obesity & metabolism	2023	Nonrandomized study	PMID 36809678 DOI	registry reference BACKGROUND:36809678